Today: 9 June 2026
OCBC share price rebounds after Monday dip as broker turns cautious and Fed looms
27 January 2026
1 min read

OCBC share price rebounds after Monday dip as broker turns cautious and Fed looms

Singapore, Jan 27, 2026, 15:02 SGT — Regular session

  • OCBC shares climbed roughly 1.4% in afternoon trading, despite a wider retreat in Singapore bank stocks on Monday
  • Phillip Securities downgraded its rating to neutral, setting a S$20 target, which sits below the current trading price
  • Traders are eyeing the U.S. Federal Reserve’s decision set for Jan. 28, along with OCBC’s full-year results coming Feb. 25

OCBC shares edged higher on Tuesday, clawing back some ground after recent losses, despite a local broker warning of limited upside following the stock’s strong run. The bank was trading up 1.38% at S$21.33 by 2:53 p.m. Singapore time, according to delayed exchange figures.

This matters since Singapore’s major banks now act as a stand-in for changing interest-rate bets. The U.S. Federal Reserve meets this week, and OCBC reports its annual results next month, pushing investors to weigh if the easiest gains in the rally have already passed.

Monday saw sharp selling pressure. OCBC dropped 1.2% to S$21.04, while DBS and UOB also declined, pulling the Straits Times Index down 0.6%.

Phillip Securities has cut OCBC’s rating to “neutral” from “accumulate,” maintaining a S$20 price target, MT Newswires reports. The stock was already trading above that level on Tuesday, limiting upside unless new earnings surprises emerge. MarketScreener Saudi Arabia

Macro factors have returned to the spotlight. “Mr Vishnu Varathan, head of macro research for Asia ex-Japan at Mizuho Securities in Singapore,” told local media he anticipates the Fed will hold policy rates steady—a stance that’s gained broad acceptance in markets ahead of the decision. The Straits Times

Reuters says the Fed is likely to keep rates steady at 3.50%-3.75% during this week’s meeting. However, political pressures on the central bank are creating extra uncertainty.

OCBC’s next major event is its full-year 2025 earnings, set for Feb. 25 on the bank’s investor calendar. Market watchers often use that report to reassess net interest margin—the gap between loan earnings and funding costs—as well as credit expenses.

Bulls face a key risk if margins shrink quicker than anticipated—especially if global rate cuts come earlier or credit provisions climb from current levels. Another straightforward threat: valuation. Since shares have already surpassed several broker targets, even a small downgrade in guidance could sting more than usual.

Traders are set to focus on the Fed’s rate decision and Chair Jerome Powell’s press conference on Wednesday, Jan. 28 for hints on the future path. After that, eyes will shift to OCBC’s earnings report due Feb. 25.

Stock Market Today

  • Regentis Biomaterials Plans European Surgeon Training for GelrinC Implant
    June 9, 2026, 9:53 AM EDT. Regentis Biomaterials' shares edged down to $1.28 ahead of the New York open as the company outlined its European launch strategy for GelrinC, a knee cartilage repair hydrogel implant. The Israeli regenerative-medicine firm will begin surgeon training in Q3 at Humanitas Research Hospital in Milan, marking a key step between CE Mark regulatory clearance and commercial use in Europe. GelrinC's "off-the-shelf" design contrasts with custom-grown products, aiming to ease adoption. However, key uncertainties remain around FDA approval in the U.S., clinical trial outcomes, market acceptance, reimbursement, and competition from established implants by Smith+Nephew and Vericel. Regentis raised $10 million at its December 2025 IPO to fund pivotal U.S. trials and PMA submission. CEO Dr. Ehud Geller called training "critical" for physician adoption ahead of broader rollout.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Exxon Mobil stock dips after hours as Baytown freeze and carbon-capture launch set up earnings week
Previous Story

Exxon Mobil stock dips after hours as Baytown freeze and carbon-capture launch set up earnings week

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom
Next Story

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom

Go toTop